Key Takeaways
Key players operating in the lupus therapeutic market are Pfizer Inc., Abbott Laboratories, AstraZeneca Plc., Novartis AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Sanofi S.A. Key players such as Pfizer Inc., AbbVie are focusing on developing novel biologics for lupus treatment.
The growing prevalence of lupus disease globally is driving the demand for effective therapeutics. According to Lupus Foundation of America, about 1.5 million Americans and at least 5 million people worldwide have a form of lupus. Rising awareness about lupus care and high unmet medical needs are also supporting the growth of the lupus therapeutic market.
The major players in the Lupus Therapeutic Market Size are focusing on expanding their footprint in developing economies in the Asia Pacific and Latin America regions where the incidence of lupus is increasing at a faster pace. In the coming years, these players are expected to launch affordable biosimilars which will provide significant cost benefits in low and middle-income countries.
Market Drivers
Increasing research activities for developing novel biologic therapeutics is a major growth driver for the lupus therapeutic market. Biologics such as belimumab (Benlysta) have demonstrated high efficiency in lupus treatment and there are many promising biologics in pipeline which are expected to get approved by 2027. This will provide fresh growth opportunities. Furthermore, rising prevalence of lupus disease globally due to urbanization and changing lifestyles is increasing the demand for innovative treatment therapies for this autoimmune condition.
Get more insights, On Lupus Therapeutic Market
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian